PT-141

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist, derived from Melanotan-II. It is studied in research for its activity at melanocortin 3 and 4 receptors (MC3R/MC4R) and its role in central nervous system signaling pathways related to melanocortin biology.

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with primary activity at MC3R and MC4R. It is studied in research for its central melanocortin signaling properties and receptor pharmacology. Supplied as a lyophilized research peptide.

PT-141 was developed from Melanotan-II at the University of Arizona by researchers exploring melanocortin receptor pharmacology. Unlike its parent compound, PT-141 was characterized as having primary activity at central MC3R and MC4R rather than peripheral MC1R. Its cyclic structure was derived through metabolic studies of Melanotan-II degradation products.

Preclinical studies demonstrate that PT-141 activates MC3R and MC4R signaling through cAMP-dependent pathways in neuronal cell models. Animal studies have characterized its effects on central melanocortin system-mediated behaviors. Research has examined its receptor binding profile, selectivity across the melanocortin receptor family, and downstream signaling kinetics in various CNS models.